Ticker Hub
IONS — AI Analysis & Sentiment
6 recent AI-generated analyses for IONS. Sentiment and confidence insights updated continuously.
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Ionis' partner GSK reported strong Phase 3 data for bepirovirsen in chronic hepatitis B, showing high functional cure rates. This significantly de-...
May 28, 2026Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
Biogen's decision to advance Ionis' Alzheimer's drug, diranersen, to registrational development provides a significant positive catalyst for Ionis,...
May 14, 2026Ionis reports first quarter 2026 financial results and highlights progress on key programs
Ionis delivered strong first-quarter results and raised its full-year guidance, driven by increasing product sales and pipeline progress. This sugg...
Apr 29, 2026Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
Ionis' bepirovirsen secured crucial FDA designations, accelerating its path to market for chronic hepatitis B. This milestone significantly de-risk...
Apr 28, 2026Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
Ionis's new positive pivotal study data for zilganersen substantially increases its chances of FDA approval for Alexander disease, presenting a cle...
Apr 21, 2026Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
Ionis received FDA Priority Review for zilganersen, a drug for a rare neurological disease with no current treatment, which is a significant positi...
Mar 23, 2026